Countdown to Ethereum Pectra Upgrade Activation: Learn more
$2.6T
Total marketcap
$254.97B
Total volume
BTC 60.35%     ETH 7.28%
Dominance

Tonix Pharmaceuticals Holding TNXP Stock

17.8 USD {{ price }} 13.810735% {{change_pct}}%
Exchange
NasdaqCM
Market Cap
122.43M USD
LOW - HIGH [24H]
14.21 - 18.25 USD
VOLUME [24H]
1.23M USD
{{ volume }}
P/E Ratio
0
Earnings per share
-176.6 USD

Tonix Pharmaceuticals Holding Price Chart

Tonix Pharmaceuticals Holding TNXP Financial and Trading Overview

Tonix Pharmaceuticals Holding stock price 17.8 USD
Previous Close 15.21 USD
Open 14.35 USD
Bid 14.61 USD x 100
Ask 15 USD x 100
Day's Range 13.71 - 18 USD
52 Week Range 11.8 - 1248 USD
Volume 2.04M USD
Avg. Volume 1.23M USD
Market Cap 83.74M USD
Beta (5Y Monthly) 2.077
PE Ratio (TTM) N/A
EPS (TTM) -176.6 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 583.33 USD

TNXP Valuation Measures

Enterprise Value 8.21M USD
Trailing P/E N/A
Forward P/E -0.4846328
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 6.72217
Price/Book (mrq) 0.26002428
Enterprise Value/Revenue 0.659
Enterprise Value/EBITDA -0.09

Trading Information

Tonix Pharmaceuticals Holding Stock Price History

Beta (5Y Monthly) 2.077
52-Week Change -98.58%
S&P500 52-Week Change 20.80%
52 Week High 1248 USD
52 Week Low 11.8 USD
50-Day Moving Average 29.91 USD
200-Day Moving Average 107.72 USD

TNXP Share Statistics

Avg. Volume (3 month) 1.23M USD
Avg. Daily Volume (10-Days) 1.8M USD
Shares Outstanding 1.87M
Float 22M
Short Ratio 0.35
% Held by Insiders 0.16%
% Held by Institutions 0.22%
Shares Short 7.67M
Short % of Float 5.48%
Short % of Shares Outstanding 5.48%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1:100

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2023
Most Recent Quarter (mrq) June 30, 2024
Next Fiscal Year End December 31, 2024

Profitability

Profit Margin 0%
Operating Margin (ttm) -831.47%
Gross Margin 21.59%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -51.72%
Return on Equity (ttm) -163.24%

Income Statement

Revenue (ttm) 12.46M USD
Revenue Per Share (ttm) 6.35 USD
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) 2.69M USD
EBITDA -90770000 USD
Net Income Avi to Common (ttm) -149012000 USD
Diluted EPS (ttm) -8039
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 4.16M USD
Total Cash Per Share (mrq) 0.19 USD
Total Debt (mrq) 9.26M USD
Total Debt/Equity (mrq) 21.99 USD
Current Ratio (mrq) 1.147
Book Value Per Share (mrq) 57.61

Cash Flow Statement

Operating Cash Flow (ttm) -73219000 USD
Levered Free Cash Flow (ttm) -44012248 USD

Profile of Tonix Pharmaceuticals Holding

Country United States
State NJ
City Chatham
Address 26 Main Street
ZIP 07928
Phone 862 799 8599
Website https://www.tonixpharma.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 103

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Q&A For Tonix Pharmaceuticals Holding Stock

What is a current TNXP stock price?

Tonix Pharmaceuticals Holding TNXP stock price today per share is 17.8 USD.

How to purchase Tonix Pharmaceuticals Holding stock?

You can buy TNXP shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Tonix Pharmaceuticals Holding?

The stock symbol or ticker of Tonix Pharmaceuticals Holding is TNXP.

Which industry does the Tonix Pharmaceuticals Holding company belong to?

The Tonix Pharmaceuticals Holding industry is Biotechnology.

How many shares does Tonix Pharmaceuticals Holding have in circulation?

The max supply of Tonix Pharmaceuticals Holding shares is 6.88M.

What is Tonix Pharmaceuticals Holding Price to Earnings Ratio (PE Ratio)?

Tonix Pharmaceuticals Holding PE Ratio is now.

What was Tonix Pharmaceuticals Holding earnings per share over the trailing 12 months (TTM)?

Tonix Pharmaceuticals Holding EPS is -176.6 USD over the trailing 12 months.

Which sector does the Tonix Pharmaceuticals Holding company belong to?

The Tonix Pharmaceuticals Holding sector is Healthcare.

Tonix Pharmaceuticals Holding TNXP included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 15603.26 USD
+0.1
9.99B USD 14784.03 USD 16292.28 USD 9.99B USD
Stlmt ID NASDAQ Biotechnology NBX 4153.28 USD
+1.21
4281.91 USD 4648.11 USD
NASDAQ Composite Total Return I XCMP 19098.57 USD
+0.1
18095.83 USD 19941.93 USD
NASDAQ Biotechnology NBI 3856.67 USD
-1.22
3700.88 USD 3966.57 USD
NASDAQ HealthCare IXHC 865.57 USD
-0.49
828.4 USD 890 USD